Recce Pharmaceuticals receives approval for Phase III DFI trial in Indonesia

By Yahoo! Finance   |   2 years ago
Recce Pharmaceuticals receives approval for Phase III DFI trial in Indonesia

Recce Pharmaceuticals has received approval for a Phase III trial of RECCE 327 (R327G) in Indonesia for diabetic foot infections. The study aims to enroll 300 patients, with results expected by the end of 2025.

Read More

Did you find this insightful?